Logo

Sequenom Shares Slide on Nasdaq Delisting Warning

Sep 20, 2005

NEW YORK, Sept. 20 (GenomeWeb News) - Shares of Sequenom's stock are down 4.88 percent, or $.04, at $.78 today following news this morning that the company has received a delisting warning letter from the Nasdaq exchange.

 

Sequenom received the letter from Nasdaq's listing qualifications department because the company's shares do not comply with Nasdaq's $1 minimum bid price requirement.

 

Sequenom now has 180 days, or until March 15, 2006, to regain compliance by closing at or above $1 per share for at least 10 consecutive business days. If the company does not regain compliance by this deadline, its common stock could be delisted from the exchange.

Breaking News
The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.